In some cases, TLR7 stimulation of T cells alone is sufficient for anti-tumor responses: nanoparticle delivery of R848 to CD8+ T cells results in increased anti-tumor immunity and prolonged survival in a murine colorectal cancer model20. The gene discussed is CD8A; the disease is neoplasm.